drugset / Trial / NCT02817217
The DDI Study of SP2086 and Valsartan
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to investigate the potential PK interaction between SP2086 and Valsartan after multiple oral doses treatment in healthy male volunteers.
Timeline
- Start
- 2016-03
- Primary completion
- 2016-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Retagliptin | Small molecule | 100 mg | Oral |
| Subject | Valsartan | Small molecule | 160 mg | Oral |